X
40.42
-0.42 (-1.03%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Xenon Pharmaceuticals Inc. | Bearish | Bullish |
Stockmoo Score
0.8
|
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fmr Llc | 30 Jun 2024 | 6,768,173 |
| Avoro Capital Advisors Llc | 30 Jun 2024 | 5,666,666 |
| Driehaus Capital Management Llc | 30 Jun 2024 | 4,419,472 |
| Commodore Capital Lp | 30 Jun 2024 | 2,754,266 |
| Capital World Investors | 30 Jun 2024 | 2,681,537 |
| Braidwell Lp | 30 Jun 2024 | 2,560,573 |
| Polar Capital Holdings Plc | 30 Jun 2024 | 2,536,058 |
| Capital International Investors | 30 Jun 2024 | 2,475,859 |
| Adage Capital Partners Gp, L.L.C. | 30 Jun 2024 | 1,839,555 |
| Alliancebernstein L.P. | 30 Jun 2024 | 1,483,166 |
| Pictet Asset Management Holding Sa | 30 Jun 2024 | 1,479,491 |
| T. Rowe Price Investment Management, Inc. | 30 Jun 2024 | 1,439,903 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 65.00 (Cantor Fitzgerald, 60.82%) | Buy |
| Median | 57.50 (42.27%) | |
| Low | 49.00 (Wedbush, 21.24%) | Buy |
| Average | 57.25 (41.65%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 39.60 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 03 Sep 2024 | 55.00 (36.08%) | Buy | 40.15 |
| 18 Jun 2024 | 55.00 (36.08%) | Buy | 36.25 | |
| Needham | 12 Aug 2024 | 60.00 (48.45%) | Buy | 38.85 |
| Cantor Fitzgerald | 09 Aug 2024 | 65.00 (60.82%) | Buy | 39.70 |
| Wedbush | 09 Aug 2024 | 49.00 (21.23%) | Buy | 39.70 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Sep 2024 | Announcement | Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress |
| 12 Aug 2024 | Announcement | Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer |
| 01 Aug 2024 | Announcement | Xenon to Report Q2 2024 Financial Results on August 8, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |